Tennessee Alzheimer's Project
Aging · Alzheimer Disease · Biomarker · Cognitive Dysfunction · Mild Cognitive Impairment · Dementia · Cognition
De qué trata este estudio
El registro indica que este estudio recluta participantes. La disponibilidad puede variar por centro.
- Tipo de estudio
- Observacional
- Fase
- No aplica / no indicada
- Rango de edad
- 60 años - No especificado
- Sexo admitido
- Todos los sexos
- Voluntarios sanos
- Aceptados
- Participantes
- 1000 Estimado
Estos son puntos de partida, no una decisión de elegibilidad. El equipo debe revisar todos los requisitos.
Las explicaciones y la navegación están en español. Los textos proporcionados por el registro, incluidos títulos, resúmenes y criterios, se conservan en su idioma original. Puedes pedir orientación en español a WCR.
Acerca de la investigación
The primary objective of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide local and national researchers with access to a well-characterized and diverse clinical cohort, including participant referrals, biosamples, clinical data, and neuroimaging data. The VADRC Clinical Core will create an infrastructure to support research efforts of both local and national investigator studies to develop early detection, prevention, and treatment strategies for Alzheimer's disease. The Clinical Core intends to enroll up to 1000 participants, including individuals who are cognitively unimpaired, have mild cognitive impairment, or have Alzheimer's disease. This cohort of about 1000 participants will be called the Tennessee Alzheimer's Project. Participants will be seen annually for comprehensive clinical characterization and then referred to other studies to enhance Alzheimer's disease research activities.
Leer la descripción completa
Alzheimer's disease (AD) is a growing public health crisis affecting 5.8 million Americans. With the aging population, AD prevalence is expected to double by 2040. Successful AD prevention and effective therapies require distilling complexities of the disease to better model disease onset, progression, and treatment response. The purpose of the Vanderbilt Alzheimer's Disease Research Center (VADRC) is to provide a better understanding of AD and related dementias, and to serve as the institutional hub of clinical, research, and educational initiatives in AD. The Center will play an essential role in expanding AD discoveries and reducing the burden of AD locally and nationally. To do so, the VADRC will support multiple human studies and model systems research over the coming years. For the Tennessee Alzheimer's Project, the team will establish, phenotype, and annually follow a cohort of adults age 60 and older with and without memory problems. Phenotyping will include standardized protocols implemented across the entire national ADRC network as part of the National Alzheimer's Coordinating Center as well as protocols specific to our local site, including (but not limited to) venous blood draw, questionnaires, physical examination, echocardiogram, neuropsychological assessment, multi-modal neuroimaging, and cerebrospinal fluid acquisition via lumbar puncture. As part of the Center's autopsy program, the investigators will ask all Tennessee Alzheimer's Project participants to consider post-mortem donation of their brain, eyes, and a small skin sample. While fluid and neuroimaging biomarkers exist for some neuropathologies associated with AD and related dementias, postmortem characterization is the only current way to definitively confirm the presence and severity of disease. Locally, a robust tissue bank with excellent ante-mortem phenotyping will provide invaluable tissue for analyses distilling the complexities of AD.
¿Quién podría participar?
La lista siguiente contiene el texto del patrocinador. Puede incluir condiciones, tratamientos previos, resultados de pruebas y otros requisitos. Aparecer en tu búsqueda no significa que califiques.
Inclusion Criteria:
- Age 60 or older
- Meet standard criteria for (a) cognitively unimpaired, (b) mild cognitive impairment, or (c) Alzheimer's disease
- English speaking
- Individuals who lack decisional capacity to provide informed consent at baseline will not be enrolled in the study
Exclusion Criteria:
- No available reliable study partner (reliable is defined as someone who interacts significantly with the participant and is available to participate in study visits in person or by phone)
- History of major psychiatric illness (e.g., schizophrenia, bipolar), neurological illness (e.g., epilepsy, multiple sclerosis, Parkinson's disease), or head injury with significant loss of consciousness.
- Unable to undergo MRI (e.g., claustrophobia, ferrous metal in body)
Población del estudio
Community-dwelling older adults.
Entiende la evaluación inicialTratamiento, grupos y participación
El registro puede describir tratamientos y duración sin incluir un calendario completo. Pide al equipo las visitas, procedimientos, riesgos, costos y alternativas. Mantén tu atención habitual salvo que tu médico te indique un cambio.
- Asignación
- No informado
- Enmascaramiento
- No informado
Cognitively unimpaired
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Other: none, observational study
Mild cognitive impairment
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Other: none, observational study
Alzheimer's disease
A consensus team determined cognitive status according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines.
Other: none, observational study
none, observational study OTHER
none, observational study
Qué evalúan los investigadores
Estas medidas indican qué se estudia. No prueban que un tratamiento funcione.
Medidas principales
Cognitive status
Plazo: baseline to year 3
Change in cognitive status assessed by the Uniform Dataset according to the National Institute on Aging and Alzheimer's Association Workgroup guidelines determined by a consensus team.
APOE Genotype
Plazo: baseline to year 3
APOE e4 allele status
White matter hyperintensities Volume
Plazo: baseline to year three
White matter lesion volume measured by FLAIR imaging modality
Grey Matter Volume
Plazo: baseline to year three
Grey matter volume measured by T1 imaging modality
Cerebral Blood Flow
Plazo: baseline to year three
Resting cerebral blood flow to brain regions measured by T3 perfusion
Lacunar infarcts
Plazo: baseline to year three
Number of lacunar infarcts measured by MRI
Microbleeds
Plazo: baseline to year three
Number of microbleeds measured by MRI
Left ventricular ejection fraction
Plazo: baseline to year three
Left ventricular ejection fraction measured by echocardiogram
Cardiac output
Plazo: baseline to year three
Amount of blood the heart pumps from each ventricle per minute (litres per minute (L/min)), measured by echocardiogram
Stroke volume
Plazo: baseline to year three
Stroke volume measured by echocardiogram
Heart rate
Plazo: baseline to year three
Heart rate measured by echocardiogram
Biological markers for Alzheimer's disease
Plazo: baseline to year three
Tau, amyloid, and neurodegenerative levels in cerebrospinal fluid samples
Blood based biological marker for Alzheimer's disease
Plazo: baseline to year three
Tau, amyloid, and neurodegenerative levels in blood samples
Revisa las tablas completas y sus limitaciones en el registro oficial.
Abrir resultados oficiales ↗Centros de investigación (1)
El estado general puede diferir del estado de un centro. Confirma la disponibilidad antes de trasladarte.
1 centros
Vanderbilt University Medical CenterNashville, Tennessee, United StatesReclutando
Equipo y fechas
- Patrocinador principal
- Vanderbilt University Medical Center
- Inicio del estudio
- 27 oct 2021 Real
- Finalización primaria
- 31 mar 2030 Estimado
- Finalización del estudio
- 31 mar 2030 Estimado
- Primera publicación
- 12 may 2022 Real
- Última actualización
- 10 nov 2026 Real
Contactos oficiales del estudio
Título oficial del estudio
Tennessee Alzheimer's Project
Consulta a Wellness Clinical Research
Tu mensaje va a WCR, incluso si otra organización realiza este estudio. WCR puede orientarte, pero podría no realizar este estudio, tener acceso a su equipo ni poder inscribirte.
Fuente: API v2 de ClinicalTrials.gov. Patrocinadores e investigadores envían la información. La NLM no aprueba la seguridad ni la ciencia de todos los estudios registrados. Aviso del registro.
Consultado: 12 nov 2026 · Última actualización del registro: 10 nov 2026